Technology area: Biotechnology & Pharmaceuticals
46 pending office actions • 17 clients • 38 examiners • 23 art units • 0 of 46 (0%) have an AI response strategy ready
Johnson, Marcou, Isaacs & Nix, LLC focuses on Biotechnology & Pharmaceuticals and reports 2177 career applications. Its resolved allowance rate is 84.75%, with 47 pending office actions. The application figure indicates a substantial prosecution record, while the allowance rate summarizes results among resolved matters.
The firm averages 4.85 office actions per allowance, indicating that allowed matters have generally required several examination exchanges. The 47 pending office actions identify an active current docket requiring continued monitoring. For clients evaluating prosecution support, the 84.75% resolved allowance rate should be considered alongside the higher examination activity reflected by the average-action figure and the present workload.
Based on the USPTO statutory response window for each pending office action. 14 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 14 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 8 (17%) |
| §103 only | 8 (17%) |
| §112 only | 9 (20%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 8 (17%) |
| Multi-statute (no §101) | 10 (22%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEHBE, ANNE MARIE SABRINA | 3 | 57.3% | +43.3% |
| HUTSON, RICHARD G | 3 | 65.1% | +52.9% |
| RAMIREZ, DELIA M | 3 | 65.1% | +56.3% |
| MARVICH, MARIA | 2 | 55.0% | +28.0% |
| RYAN, DOUGLAS CHARLES | 2 | 38.2% | +48.4% |
| FENSTERMACHER, JASON B | 1 | 47.3% | +37.4% |
| KIEFER, DALTON EDWARD | 1 | 85.7% | +16.7% |
| GRAHAM, ANDREW D | 1 | 59.8% | +23.3% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| SINGH, ANOOP KUMAR | 1 | 43.2% | +67.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248199 | HELITRON MEDIATED GENETIC MODIFICATION | LIPPOLIS, ALEXANDRA ROSE | 25d overdue |
| 18277904 | SURFACTANT COMPOSITIONS | OGDEN JR, NECHOLUS | 8d overdue |
| 17600799 | METHODS AND COMPOSITIONS FOR CELL THERAPY | JOHNSON, ALLISON MARIE | 14d |
| 17786168 | GENOME EDITING USING REVERSE TRANSCRIPTASE ENABLED AND FULLY ACTIVE CRISPR COMPLEXES | LEE, JAE W | 33d |
| 17616621 | CRISPR SYSTEM HIGH THROUGHPUT DIAGNOSTIC SYSTEMS AND METHODS | POHNERT, STEVEN C | 53d |
| 19218176 | Electronic Proxy Voting Systems and Methods | FENSTERMACHER, JASON B | — |
| 18932763 | PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS | KIEFER, DALTON EDWARD | — |
| 18708739 | DIHYDROPYRROLO[3,4C]-PYRAZOLE DERIVATIVES AND THEIR USE IN DIAGNOSIS | DONOHUE, SEAN R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17707951 | ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS | WEHBE, ANNE MARIE SABRINA | 99d overdue |
| 17085937 | BACTERIAL DEFENSE SYSTEMS AND METHODS OF IDENTIFYING THEREOF | RYAN, DOUGLAS CHARLES | 3d overdue |
| 16450825 | NOVEL CRISPR ENZYMES AND SYSTEMS | RAMIREZ, DELIA M | 14d |
| 16954032 | CAS12A SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED RNA BASE EDITING | HUTSON, RICHARD G | 20d |
| 18849107 | THREE DIMENSIONAL PRINTING PROCESS FLOW MANAGEMENT AND SUPPORT SYSTEMS | GRAHAM, ANDREW D | 53d |
| 19449304 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | MARVICH, MARIA | — |
| 19390128 | ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS | WEHBE, ANNE MARIE SABRINA | — |
| 19355982 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | MARVICH, MARIA | — |
| Client (Assignee) | Pending OAs |
|---|---|
| MIT | 26 |
| Harvard University | 4 |
| U.S. Government | 2 |
| Proxymity Limited | 1 |
| Azul 3D, Inc. | 1 |
| AC IMMUNE SA | 1 |
| Virginia Tech | 1 |
| Defence Therapeutics Inc. | 1 |
| THE BROAD INSTITUTE, INC. | 1 |
| Nestlé S.A. | 1 |
| DANA-FARBER CANCER INSTITUTE, INC. | 1 |
| Lankem | 1 |
| California Institute of Technology | 1 |
| Wti, Inc. | 1 |
| THE GENERAL HOSPITAL CORPORATION | 1 |
| The Brigham and Women's Hospital Inc. | 1 |
| EPAX NORWAY AS | 1 |
| Art Unit | Apps |
|---|---|
| 1652 | 8 |
| 1634 | 5 |
| 1637 | 4 |
| 1636 | 4 |
| 1632 | 3 |
| 1633 | 3 |
| 1635 | 2 |
| 1656 | 2 |
| 3698 | 1 |
| 1742 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19449304 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | Massachusetts Institute Of Technology | MARVICH, MARIA | 1634 | §112 | Non-Final OA | — | Pending | Jan 14, 2026 |
| 19390128 | ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS | Massachusetts Institute Of Technology | WEHBE, ANNE MARIE SABRINA | 1634 | §103 | Final Rejection | — | Pending | Nov 14, 2025 |
| 19355982 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | Massachusetts Institute Of Technology | MARVICH, MARIA | 1634 | §112DP | Non-Final OA | — | Pending | Oct 10, 2025 |
| 19218176 | Electronic Proxy Voting Systems and Methods | Proxymity Limited | FENSTERMACHER, JASON B | 3698 | §101§112 | Final Rejection | — | Pending | May 23, 2025 |
| 18965935 | NOVEL TYPE VI CRISPR ENZYMES AND SYSTEMS | Massachusetts Institute Of Technology | RYAN, DOUGLAS CHARLES | 1635 | §112 | Non-Final OA | — | Pending | Dec 02, 2024 |
| 18932763 | PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS | Massachusetts Institute Of Technology | KIEFER, DALTON EDWARD | 1652 | §102§103§112Other | Non-Final OA | — | Pending | Oct 31, 2024 |
| 18849107 | THREE DIMENSIONAL PRINTING PROCESS FLOW MANAGEMENT AND SUPPORT SYSTEMS | Azul 3D, Inc. | GRAHAM, ANDREW D | 1742 | §103 | Final Rejection | 53d | Pending | Sep 20, 2024 |
| 18708739 | DIHYDROPYRROLO[3,4C]-PYRAZOLE DERIVATIVES AND THEIR USE IN DIAGNOSIS | Ac Immune SA | DONOHUE, SEAN R | 1618 | §103§112Other | Non-Final OA | — | Pending | May 09, 2024 |
| 18698929 | ENGINEERED CARDIAC MUSCLE COMPOSITIONS | Massachusetts Institute Of Technology | SINGH, ANOOP KUMAR | 1632 | §102§103§112DP | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18628213 | NANOPOROUS ALLOYS | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | WANG, XIAOBEI | 1784 | §103 | Non-Final OA | 140d overdue | Pending | Apr 05, 2024 |
| 18689897 | ENGINEERED MUSCLE AND CENTRAL NERVOUS SYSTEM COMPOSITIONS | Massachusetts Institute Of Technology | PYLA, EVELYN Y | 1633 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 07, 2024 |
| 18686538 | STEROID ACID-BASED HYDROGELS | Defence Therapeutics Inc. | STEELE, AMBER D | 1658 | §103§112DP | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18580716 | ENGINEERED TARGETING COMPOSITIONS FOR ENDOTHELIAL CELLS OF THE CENTRAL NERVOUS SYSTEM VASCULATURE AND METHODS OF USE THEREOF | The Broad Institute, Inc. | LEONARD, ARTHUR S | 1631 | §102§112DP | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18576909 | METHODS FOR DIFFERENTIATING AND SCREENING STEM CELLS | Massachusetts Institute Of Technology | WESTON, ALYSSA G | 1633 | §101§102§112 | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18574816 | BIFIDOBACTERIUM LONGUM TRANSITIONAL MICROORGANISMS, COMPOSITIONS AND USES THEREOF | Société des Produits Nestlé S.A. | DICKENS, AMELIA NICOLE | 1645 | §101§102§103§112DP | Non-Final OA | — | Pending | Dec 28, 2023 |
| 18541680 | METHODS AND COMPOSITIONS FOR PREDICTING AND PREVENTING RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA | DANA-FARBER CANCER INSTITUTE, INC. | DAVIS, BRIAN J | 1614 | §102§112 | Final Rejection | — | Pending | Dec 15, 2023 |
| 18277904 | SURFACTANT COMPOSITIONS | Lankem Ltd. | OGDEN JR, NECHOLUS | 1761 | §101§102§103§112 | Final Rejection | 8d overdue | Pending | Aug 18, 2023 |
| 18271684 | REPROGRAMMABLE TNPB POLYPEPTIDES AND USE THEREOF | Massachusetts Institute Of Technology | TATGE, LEXUS MARC | 1637 | §101§102§103§112DP | Non-Final OA | — | Pending | Jul 11, 2023 |
| 18349707 | NOVEL CAS13B ORTHOLOGUES CRISPR ENZYMES AND SYSTEMS | Massachusetts Institute Of Technology | HUTSON, RICHARD G | 1652 | §102§112DP | Non-Final OA | — | Pending | Jul 10, 2023 |
| 18270131 | CROSS-NEUTRALIZING SARS-COV2 ANTIBODIES | California Institute Of Technology | JADHAO, SAMADHAN JAISING | 1672 | §101§112 | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18249865 | NUCLEIC ACID-GUIDED NUCLEASES AND USE THEREOF | Massachusetts Institute Of Technology | EBBINGHAUS, BRIANA NOEL | 1632 | §112 | Final Rejection | — | Pending | Apr 20, 2023 |
| 18032868 | REPROGRAMMABLE ISCB NUCLEASES AND USES THEREOF | Massachusetts Institute Of Technology | SU-TOBON, QIWEN NMN | 1636 | §112DP | Final Rejection | 9d | Pending | Apr 20, 2023 |
| 18248199 | HELITRON MEDIATED GENETIC MODIFICATION | Massachusetts Institute Of Technology | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103 | Non-Final OA | 25d overdue | Pending | Apr 06, 2023 |
| 17928355 | CRISPR-ASSOCIATED TRANSPOSASE SYSTEMS AND METHODS OF USE THEREOF | Massachusetts Institute Of Technology | STAVROU, CONSTANTINA E | 1632 | §103Other | Final Rejection | — | Pending | Nov 29, 2022 |
| 17910497 | NOVEL CAS ENZYMES AND METHODS OF PROFILING SPECIFICITY AND ACTIVITY | Massachusetts Institute Of Technology | CHONG, KIMBERLY | 1636 | §112 | Non-Final OA | — | Pending | Sep 09, 2022 |
| 17786168 | GENOME EDITING USING REVERSE TRANSCRIPTASE ENABLED AND FULLY ACTIVE CRISPR COMPLEXES | Massachusetts Institute Of Technology | LEE, JAE W | 1656 | §102§103§112 | Final Rejection | 33d | Pending | Jun 16, 2022 |
| 17742127 | NOVEL CRISPR ENZYMES AND SYSTEMS | Massachusetts Institute Of Technology | LEITH, NANCY J | 1636 | §103§112DP | Non-Final OA | — | Pending | May 11, 2022 |
| 17707951 | ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS | Massachusetts Institute Of Technology | WEHBE, ANNE MARIE SABRINA | 1634 | §103 | Final Rejection | 99d overdue | Pending | Mar 30, 2022 |
| 17642541 | ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS | Massachusetts Institute Of Technology | WEHBE, ANNE MARIE SABRINA | 1634 | §102§103 | Final Rejection | — | Pending | Mar 11, 2022 |
| 17689036 | CONCENTRATED NATURAL FOOD ADDITIVE AND METHODS OF PREPARING THE SAME | Wti, Inc. | MORNHINWEG, JEFFREY P | 1793 | §103§112 | Non-Final OA | — | Pending | Mar 08, 2022 |
| 17638355 | CRISPR-ASSOCIATED MU TRANSPOSASE SYSTEMS | Massachusetts Institute Of Technology | SMALL, KATHERINE R | 1633 | §101§102Other | Non-Final OA | — | Pending | Feb 25, 2022 |
| 17681479 | NON-NATURALLY OCCURRING CAPSIDS FOR DELIVERY OF NUCLEIC ACIDS AND/OR PROTEINS | Massachusetts Institute Of Technology | QIAN, CELINE X | 1637 | §103 | Final Rejection | — | Pending | Feb 25, 2022 |
| 17616621 | CRISPR SYSTEM HIGH THROUGHPUT DIAGNOSTIC SYSTEMS AND METHODS | The General Hospital Corporation | POHNERT, STEVEN C | 1683 | §102§103§112Other | Final Rejection | 53d | Pending | Dec 03, 2021 |
| 17612504 | NOVEL CRISPR-CAS SYSTEMS AND USES THEREOF | Massachusetts Institute Of Technology | MOAZZAMI, NAGHMEH NINA | 1652 | §103 | Final Rejection | — | Pending | Nov 18, 2021 |
| 17600799 | METHODS AND COMPOSITIONS FOR CELL THERAPY | The Brigham And Women'S Hospital, Inc. | JOHNSON, ALLISON MARIE | 1638 | §103§112 | Final Rejection | 14d | Pending | Oct 01, 2021 |
| 17311600 | VERY LONG CHAIN FATTY ACID COMPOSITIONS | Epax Norway AS | WHITE, DAWANNA SHAR-DAY | 1627 | §101 | Final Rejection | — | Pending | Jun 07, 2021 |
| 17254886 | CRISPR DOUBLE NICKASE BASED AMPLIFICATION COMPOSITIONS, SYSTEMS, AND METHODS | President and Fellows of Harvard College | GREENE, CAROLYN LEE | 1681 | §112 | Final Rejection | 30d overdue | Pending | Dec 22, 2020 |
| 16973061 | CRISPR EFFECTOR SYSTEM BASED AMPLIFICATION METHODS, SYSTEMS, AND DIAGNOSTICS | President and Fellows of Harvard College | RAMIREZ, DELIA M | 1652 | §103§112 | Non-Final OA | — | Pending | Dec 08, 2020 |
| 17085937 | BACTERIAL DEFENSE SYSTEMS AND METHODS OF IDENTIFYING THEREOF | Massachusetts Institute Of Technology | RYAN, DOUGLAS CHARLES | 1635 | §112 | Non-Final OA | 3d overdue | Pending | Oct 30, 2020 |
| 16954032 | CAS12A SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED RNA BASE EDITING | Massachusetts Institute Of Technology | HUTSON, RICHARD G | 1652 | §103§112DP | Final Rejection | 20d | Pending | Jun 15, 2020 |
| 16772222 | CAS12B SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED DNA BASE EDITING | Massachusetts Institute Of Technology | PERSONS, JENNA L | 1637 | §112 | Non-Final OA | — | Pending | Jun 12, 2020 |
| 16756134 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING | President and Fellows of Harvard College | STEADMAN, DAVID J | 1656 | DP | Non-Final OA | 3d overdue | Pending | Apr 15, 2020 |
| 16820590 | NON-NATURALLY OCCURRING CAPSIDS FOR DELIVERY OF NUCLEIC ACIDS AND/OR PROTEINS | Massachusetts Institute Of Technology | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Final Rejection | — | Pending | Mar 16, 2020 |
| 16626396 | NOVEL TYPE VI CRISPR ORTHOLOGS AND SYSTEMS | President and Fellows of Harvard College | HUTSON, RICHARD G | 1652 | Other | Final Rejection | — | Pending | Dec 24, 2019 |
| 16450825 | NOVEL CRISPR ENZYMES AND SYSTEMS | The United States Department of Health and Human Services | RAMIREZ, DELIA M | 1652 | §112 | Non-Final OA | 14d | Pending | Jun 24, 2019 |
| 16450699 | NOVEL CRISPR ENZYMES AND SYSTEMS | The United States Department of Health and Human Services | RAMIREZ, DELIA M | 1652 | §112 | Final Rejection | — | Pending | Jun 24, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial84.8% of resolved applications prosecuted by Johnson, Marcou, Isaacs & Nix, LLC were allowed, across 2,177 applications in USPTO records.
4.85 office actions per allowed application on average.
46 pending office actions as of October 2026, for 17 clients, before 38 examiners in 23 art units.
